cost effectiveness of vinorelbine with or without cisplatin based primarily on data from a phase III comparison with … cost data to the outcomes from the phase III trial. Using vinorelbine monotherapy or vinorelbine plus cisplatin produced a … outpatient vinorelbine plus cisplatin ranged from 7450 Canadian dollars ($Can) to $Can30 770 (1993 values) per year of life saved …

-squamous populations and erlotinib with pemetrexed in the non-squamous population. The incremental cost-effectiveness ratios (ICERs …-west corner of a cost-effectiveness plane, i.e. erlotinib is cheaper but less effective than pemetrexed. The ERG recalculated the …/or adjustments were required, related to time horizon, discounting logic, costs of erlotinib and pemetrexed, cost of second …

trial in which the reference regimen cisplatin-paclitaxel was compared with two experimental regimens: cisplatin-gemcitabine … cisplatin-gemcitabine is the least costly regimen of the two and a 72% probability that this regimen reduces costs while at the … same time improving survival. Compared with cisplatin-paclitaxel, the gemcitabine-paclitaxel regimen engendered a …

gemcitabine monotherapy. The combination of gemcitabine with cisplatin has shown good antitumour efficacy (26 to 54% objective … similar). Gemcitabine plus cisplatin produces grade 3 or 4 myelosuppression in many patients, but this has generally proved … manageable and has not limited clinical use. Data from phase III comparisons of gemcitabine plus cisplatin with currently …

Objective: To compare clinical and economic study data for docetaxel, paclitaxel and vinorelbine in the treatment of … adverse effect rates from phase III clinical trial data for docetaxel, paclitaxel and vinorelbine. Costs were taken from UK …) gained (1998 values). The incremental cost-utility ratio for docetaxel versus vinorelbine was Lstg 14 055 per QALY gained. In …

). Methods: Gemcitabine was compared with best supportive care and gemcitabine/cisplatin was compared with three standard …. In comparison with standard chemotherapies, gemcitabine/cisplatin was associated with an incremental cost per progression … gemcitabine/ cisplatin showed cost savings in each case, with the same or better outcome. Thus, gemcitabine/cisplatin showed …

Objective: To conduct an economic analysis on the use of carboplatin versus cisplatin over multiple courses in patients … with carboplatin and cisplatin administration over 3 to 6 courses of treatment were measured and compared. The perspective … received prior chemotherapy, received either carboplatin or cisplatin as their treatment (additional chemotherapy agents were …

) from the perspective of the UK NHS, based on the resources and outcomes from the pivotal clinical study comparing docetaxel … the difference in mean survival between the docetaxel group and the BSC group was calculated as 3.82 months. Measurable … incremental costs for the docetaxel group were largely driven by drug acquisition and administration. These cost drivers, as well …

treatment in combination with best supportive care) versus palliative treatment with gemcitabine in combination with best … the same population if they additionally received gemcitabine. Setting. This economic analysis is based on a hypothetical …. After exclusions, 184 patients were included in the economic analysis. Interventions. The effects of gemcitabine treatment …